Related Experiment Video

Updated: May 11, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Functional genomics lead to new therapies in follicular lymphoma

Elisa Oricchio1, Hans-Guido Wendel

  • 1Cancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA. oriccche@mskcc.org

Annals of the New York Academy of Sciences
|May 17, 2013
PubMed

Insights

Researchers identified ephrin receptor A7 (EPHA7) as a tumor suppressor in lymphoma by analyzing chromosome 6q deletions. An antibody strategy was developed to deliver EPHA7, showing potential for broader cancer therapy applications.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Technological advances enable detailed cancer genomic analysis.
  • Prioritizing genetic aberrations for therapeutic targeting remains a challenge.

Purpose of the Study:

  • To identify therapeutic targets from complex genomic data using unbiased genetic screens.
  • To investigate the role of chromosome 6q deletions in cancer.

Main Methods:

  • Utilized unbiased genetic screens and murine cancer models.
  • Genetically dissected chromosome 6q deletions.
  • Developed an antibody-based delivery strategy for EPHA7.

Main Results:

  • Identified ephrin receptor A7 (EPHA7) as a tumor suppressor in lymphoma.
  • Discovered a soluble splice variant of EPHA7 acting as an extrinsic tumor suppressor.
  • Demonstrated successful antibody-mediated delivery of EPHA7 to tumors.

Conclusions:

  • EPHA7 functions as a tumor suppressor, particularly in lymphoma.
  • Antibody-mediated delivery of EPHA7 offers a potential therapeutic strategy for cancers with EPHA7 loss.
  • This approach has broader implications for treating lung cancer and other malignancies.
Keywords:
genomic datamouse modeltherapies

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...